blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Extract from the Register of European Patents

EP About this file: EP0487591

EP0487591 - ANTICOAGULANT PROTEIN [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.10.1994
Database last updated on 30.10.2024
Most recent event   Tooltip06.10.1994No opposition filed within time limitpublished on 23.11.1994 [1994/47]
Applicant(s)For all designated states
NOVO NORDISK A/S
Novo Allé
2880 Bagsværd / DK
[N/P]
Former [1992/23]For all designated states
NOVO NORDISK A/S
Novo Allé
DK-2880 Bagsvaerd / DK
Inventor(s)01 / RASMUSSEN, Jesper, Skou
Linde Allé 50, 2. t.h.
DK-2720 Vanloese / DK
02 / NORDFANG, Ole, Juul
Selskovvej 6
DK-3400 Hilleroed / DK
[1992/23]
Representative(s)Pettersson, Poul Eisten
c/o Novo Nordisk A/S Patent Department Novo Allé
2880 Bagsvaerd / DK
[N/P]
Former [1992/23]Pettersson, Poul Eisten
c/o Novo Nordisk A/S Patent Department Novo Allé
DK-2880 Bagsvaerd / DK
Application number, filing date90912756.517.08.1990
[1992/23]
WO1990DK00212
Priority number, dateDK1989000408018.08.1989         Original published format: DK 408089
[1992/23]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9102753
Date:07.03.1991
Language:EN
[1991/06]
Type: A1 Application with search report 
No.:EP0487591
Date:03.06.1992
Language:EN
The application published by WIPO in one of the EPO official languages on 07.03.1991 takes the place of the publication of the European patent application.
[1992/23]
Type: B1 Patent specification 
No.:EP0487591
Date:01.12.1993
Language:EN
[1993/48]
Search report(s)International search report - published on:SE07.03.1991
ClassificationIPC:C07K13/00, C12N15/15, A61K37/64
[1992/23]
CPC:
C07K14/8114 (EP,US); A61P35/00 (EP); A61P7/02 (EP);
A61K38/00 (EP,US)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   IT,   LI,   LU,   NL,   SE [1992/23]
TitleGerman:ANTIKOAGULIERENDES PROTEIN[1992/23]
English:ANTICOAGULANT PROTEIN[1992/23]
French:PROTEINE ANTICOAGULANTE[1992/23]
Entry into regional phase21.01.1992National basic fee paid 
21.01.1992Designation fee(s) paid 
21.01.1992Examination fee paid 
Examination procedure04.02.1991Request for preliminary examination filed
International Preliminary Examining Authority: DE
21.01.1992Examination requested  [1992/23]
22.03.1993Despatch of communication of intention to grant (Approval: Yes)
25.05.1993Communication of intention to grant the patent
19.08.1993Fee for grant paid
19.08.1993Fee for publishing/printing paid
Opposition(s)02.09.1994No opposition filed within time limit [1994/47]
Fees paidRenewal fee
13.06.1992Renewal fee patent year 03
22.05.1993Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[A]EP0300988  (UNIV WASHINGTON [US]);
 [Y]EP0318451  (MONSANTO CO [US], et al)
 [X]  - Nature, Vol. 338, 1989 J. GIRARD et al.: "Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor", see especially p. 518 col. 2 lines 11-12, p. 520 col 1 lines 1-8.
 [A]  - Thrombosis research, Vol. 48, 1987 B.J. WARN-CRAMER et al.: "Partial Purification and characterization of extrinsic", see page 11 - page 22.
 [A]  - Proc. Natl. Acad. Sci., Vol. 84, 1987 GEORGE J. BROZE, Jr. et al.: "Isolation of the tissue factor inhibitor produced by HepG2 hepatoma cells", see page 1886 - page 1890.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.